Patent Issues in the Development of Biosimilar Medicines July 21, 2011

Biosimilar medicines are already a commercial reality in the European Union. The U.S. Healthcare Reform legislation – with its defined pathway for the regulatory approval of follow-on biologics – should open up the U.S. market in the future, but in the meantime, the next batch of biosimilars will face other difficulties in reaching the market, both in the EU and elsewhere. SMi Group provides a CPD accredited masterclass which helps industry professionals to deal with patents issues during biosimilar medicine development for the EU market.

Benefits of attending:

• Analyse the IP of biosimilars in advanced markets
• Discuss patent issues that may arise during the development of biosimilar medicines for the EU market
• Debate case studies involving IP evolution, cost effectiveness and business models
• Gain knowledge about the development of Monoclonal antibodies regulation
• Learn from an extremely experienced Masterclass leader with in-depth and specific knowledge of IP legal practice in the pharmaceutical sector
• Gain valuable CPD points through attendance

For further information and the opportunity to register, please visit the website. Alternatively, please contact Mo Saffaf via Email: [email protected] or Tel: +44 (0) 20 7827 6022

Official Website: http://www.smi-online.co.uk/biosimilarsclass23.asp